BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Reports

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
223
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Reports Promising Prophylactic Results from Preclinical Proof-of-Concept NanoAb COVID-19 Study

- BiondVax’s preclinical proof-of-concept study was designed to mimic a real-world situation regarding at-risk groups, including the elderly, people with comorbidities, the immunocompromised, travelers, those attending densely packed social events, and front-line healthcare workers
- The study shows promising prophylactic results with hamsters receiving BiondVax’s inhaled NanoAb three hours before infection experiencing no significant weight loss over the six-day trial; follows previously reported data showing successful use of NanoAb as COVID-19 therapeutic
- First-in-human Phase 1/2a clinical trial is planned for later this year

Focused on the development, manufacture, and commercialization of innovative NanoAb immunotherapeutic products, BiondVax Pharmaceuticals (NASDAQ: BVXV) recently announced additional results in the company’s preclinical proof-of-concept study of its inhaled nanosized VHH-antibody (NanoAb) COVID-19 drug (https://nnw.fm/bEwBd ). BiondVax is developing a pipeline of innovative alpaca-derived NanoAb drugs addressing diseases with large underserved medical needs and attractive commercial opportunities, such as COVID-19, asthma, psoriasis, psoriatic arthritis, and macular degeneration. The research is being done as part of a collaboration with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen.

The study was designed to mimic a real-world situation in which at-risk groups, including the elderly, people with comorbidities, the immunocompromised, travelers, those attending densely packed social events, and front-line healthcare professionals may proactively protect themselves prior to potential SARS-CoV-2 exposure using BiondVax’s self-administered inhaled NanoAb therapy.

Using an industry-standard animal model, the study compared weight loss in two groups of hamsters. The hamsters administered a mid-sized 0.66mg dose of the NanoAb three hours before infection experienced no significant weight loss over the six-day trial. In contrast, the hamsters in the untreated control group experienced a 12% decline in weight, a highly statistically significant difference (p<0.0005).

The promising prophylactic results follow previously reported data from the same study indicating that compared to the control (placebo) group, hamsters treated with a 2mg dose of BiondVax’s inhaled NanoAb one day after infection had negligible (below detection level) SARS-CoV-2 viral titers in their lungs, and experienced a milder and shorter illness compared to the placebo group that had at least 30-times higher viral titers in their lungs at the end of the trial. Additionally, lung histopathology revealed that therapeutic inhalation of NanoAbs reduced damage to alveoli, pulmonary vessels, and the conductive system.

“We continue to be thrilled with the results of this ongoing trial. There is strong market demand for COVID prophylactics as evidenced by AstraZeneca’s reported Q1 through Q3 2022 EVUSHELD revenues of $1.5 billion. EVUSHELD is currently the only prophylactic COVID medication with FDA approval under emergency use authorization,” BiondVax CEO Amir Reichman said. “Our inhaled NanoAb is designed to be self-administered at the time of choosing to generate rapid protection from COVID illness. In contrast, EVUSHELD must be administered via two separate consecutive intramuscular (‘IM’) injections in a health care setting… we believe the additional ‘biobetter’ value provided by our NanoAb potentially positions it to capture significant market share both for treatment and prevention of COVID illness.”

The preclinical trial’s next step is to continue with additional arms testing lower therapeutic doses. It will also evaluate safety parameters. The results of the dosing study will inform the design of future studies of BiondVax’s inhaled NanoAb expected in 2023, including a preclinical toxicity study to assess safety as required by regulatory authorities for approval of human clinical trials. BiondVax is also expected to scale up its manufacturing processes to produce, at its Jerusalem GMP manufacturing facility, the NanoAbs for the first-in-human Phase 1/2a clinical trial planned for Q4 2023.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://nnw.fm/BVXV

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer


BiondVax Pharmaceuticals Ltd. (BVXV) Stock Research Links

BVXV Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Perigon Builds Its Investment Bench for the Next Leg

Updated Category News Views 129

Perigon is rearranging the engine room before the next growth spurt gets noisy. The firm has named Christopher Broderick Director of Investments and Research, added two trading associates, and put another brick behind the broader operating structure Rafia Hasan has been assembling since taking on the chief operating officer role in August. That may sound like ordinary...

Continue Reading
Teachstone’s Bronze Award Puts Classroom Quality in Focus

Updated Category News Views 36

Small Classroom Moments Finally Get Their Due A child’s hesitant question can disappear in the noise of a busy classroom, which is precisely why Teachstone’s latest recognition deserves more than the usual polite golf clap. The Charlottesville-based Certified B Corporation received a Bronze Anthem Award for its “From Measurement to Momentum” initiative, in the...

Continue Reading
Sleep Number’s Couples Pitch Has Some Fine Print Too

Updated Category News Views 75

A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...

Continue Reading
CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 45

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 100

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
U.S. Employers Signal a Deeper Multilingual Skills Gap

Updated Category News Views 90

A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...

Continue Reading
Childhood Nutrition Advice That Lowers Mealtime Stress

Updated Category News Views 72

A toddler surviving on three bites Tuesday is not a verdict on the family table. That plain idea sits at the center of pediatric expert Kathy Shirazi’s guidance on childhood nutrition, and frankly, it deserves more oxygen than another impossible-looking lunchbox photo. In the HelloNation article released November 20, 2026, Shirazi, MD, MPH, FAAP, urges parents to judge...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 121

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 88

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading

Top 5 Most Recently Viewed Articles

Specialty1 Partners Drives New Growth Through Partnerships

Updated Category News Views 227

Specialty1 Partners Fuels Growth with Innovative Model Specialty1 Partners (S1P) has emerged as a leader in the specialty dental partnership sector, focusing on aiding Endodontists, Periodontists, and Oral Surgeons in elevating their practices. Their innovative joint venture model is increasingly attracting dental specialists eager to transition from associates to...

Continue Reading
Union Pacific in Talks for Major Norfolk Southern Merger

Updated Category News Views 263

Union Pacific's Ambitious Merger Talks Union Pacific Corp. (NYSE: UNP) is reportedly engaged in preliminary discussions to acquire Norfolk Southern Corp. (NYSE: NSC), marking a prospective mega-merger in the railroad industry. While details are still emerging, the implications of such a merger could significantly reshape the freight transport landscape across the United...

Continue Reading
Great Elm Capital Corp.'s Impressive Second Quarter Performance

Updated Category News Views 147

Overview of Financial Achievements Great Elm Capital Corp. (NASDAQ: GECC) has recently released its financial performance report for the second quarter, demonstrating remarkable growth and a prosperous quarter for the company. This update is essential for investors and stakeholders keen on understanding the company's current financial health and future prospects. Record...

Continue Reading
Scandinavian Tobacco Group Updates on Share Buy-back Activities

Updated Category News Views 211

Scandinavian Tobacco Group A/S launched a significant share buy-back program back in November, worth up to DKK 850 million. The move aimed at adjusting the company's capital structure and meeting obligations tied to its share-based incentive programs. This isn’t just a random act; it’s a strategic ploy in a competitive market that’s meant to bolster their stock...

Continue Reading
Breakthrough Outcomes of Telitacicept in Sjögren's Syndrome Study

Updated Category News Views 220

Exciting Developments in Telitacicept Phase III Trial Results The Phase III clinical trial results for Telitacicept are sparking significant interest, particularly within the realm of Sjögren's Syndrome. This autoimmune condition can severely affect patients' quality of life due to symptoms like dry mouth and dry eyes, among others. Recently, announcements surrounding...

Continue Reading